Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0000899243-19-000296

Chief Business Officer acquired 20,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Klein Lawrence Otto · Chief Business Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2019-01-02 Grant or award : show line 1 in the form +20,000 $29.87 $597,400 20,000 D

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2019-01-02 Grant or award : show line 2 in the form Stock Option (Right to Buy) +20,000 20,000 D
Loading xslF345X03/doc4.xml…